secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001387131-23-004420
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharmaceuticals receives Nasdaq non-compliance notice and prioritizes CNS pipeline
--------------------------------------------------------------------------------

- Received Nasdaq notice on March 31, 2023, for non-compliance with $1 minimum bid price; has 180 days until September 27, 2023 to regain compliance.
- Reallocating resources to focus on mid- and late-stage CNS programs: fibromyalgia (TNX-102 SL), depression (TNX-601 ER), migraine (TNX-1900), cocaine intoxication (TNX-1300).
- Delaying start of Phase 3 PTSD study in Kenya and discontinuing enrollment in Phase 2 Long COVID study; ~60 patients to be followed, topline data expected Q3 2023.
- Cash and cash equivalents approximately $120.2 million as of December 31, 2022; key 2023 milestones include interim Phase 3 RESILIENT data in Q2 and topline data in Q4.
- Deprioritizing COVID-19 related programs: anti-COVID antibodies (TNX-3600, -3800, -4100) and vaccines (TNX-1800, -1850); continuing TNX-801 and broad-spectrum antivirals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123004420/0001387131-23-004420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123004420/tnxp-8k_033123.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-004420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer